SCHEMBL12766232

SCHEMBL12766232

Nc1nnc(-c2ccc3cnccc3c2)[nH]1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCZ Q05513 1/20 0.49
TDO2 P48775 2/20 0.43
PRKCI P41743 1/20 0.40
CYP11B1 P15538 2/20 0.38
CYP11B2 P19099 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
PIM1 P11309 4/20 0.38
HASPIN Q8TF76 4/20 0.38
CCNT1 O60563 1/20 0.38
CDK9 P50750 1/20 0.38
AR P10275 1/20 0.38
ABL1 P00519 2/20 0.38
PIK3CD O00329 2/20 0.38
PIK3CB P42338 2/20 0.38
PIK3CG P48736 2/20 0.38
EGFR P00533 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12766238 0.81 PRKCZ (0.45) PRKCZTDO2PRKCICYP11B1CYP11B2
SCHEMBL12766231 0.77 TDO2 (0.39) PRKCZTDO2PRKCIPIM1HASPIN
SCHEMBL12766292 0.75 PRKCZ (0.49) PRKCZTDO2PRKCICYP11B1CYP11B2
SCHEMBL13258488 0.74 LMNA (0.42) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL15452781 0.71 ALDH1A1 (0.50) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL444504 0.70 PRKCZ (0.63) PRKCZTDO2CYP11B1CYP11B2CYP3A4
SCHEMBL1519932 0.69 CDK2 (0.54) PRKCZCYP1A2CYP3A4CYP2C9PIM1
SCHEMBL1594955 0.69 KDM4E (0.57) PRKCZCDK2AKT1
SCHEMBL12766093 0.69 PRKCZ (0.49) PRKCZTDO2CYP11B1CYP11B2CYP1A2
SCHEMBL15946913 0.69 PRKCZ (0.49) PRKCZTDO2PRKCICYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7897619-B2 Heterocyclic modulators of PKB AMGEN INC. (US) 2011-03-01 US disclosed
US-7897619-B2 Heterocyclic modulators of PKB AMGEN INC. (US) 2011-03-01 US disclosed
US-20090275592-A1 Heterocyclic modulators of PKB AMGEN INC. (US) 2009-11-05 US disclosed
US-20090275592-A1 Heterocyclic modulators of PKB AMGEN INC. (US) 2009-11-05 US disclosed
WO-2009011880-A2 HETEROCYCLIC MODULATORS OF PKB AMGEN INC. (US) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275592-A1 Heterocyclic modulators of PKB MTOR, PDK1, EIF4EBP1 PRKCZ 154/4885TDO2 3329/4885PRKCI 94/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.